NuVasive (Nasdaq: NUVA) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict NuVasive's revenues will expand 3.7% and EPS will grow 10.0%.

The average estimate for revenue is $157.3 million. On the bottom line, the average EPS estimate is $0.22.

Revenue details
 Last quarter, NuVasive booked revenue of $165.8 million. GAAP reported sales were 10% higher than the prior-year quarter's $150.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.34. GAAP EPS were -$0.06 for Q4 versus -$0.24 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 74.5%, 80 basis points worse than the prior-year quarter. Operating margin was 8.4%, 180 basis points better than the prior-year quarter. Net margin was -1.7%, 500 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $656.0 million. The average EPS estimate is $1.00.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 168 members out of 187 rating the stock outperform, and 19 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 34 give NuVasive a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $19.56.

Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.